The Federal Circuit heard oral argument in Auribundo's appeal of the district court's decision in favor of plaintiff Merck, in a case captioned In re Sugammadex (alternatively, Aurobindo v. Merck ...
Nature of the Case and Issue(s) Presented: Merck owned U.S. Patent No. 6,670,340 (“the ‘’340 patent”), which issued on Dec. 30, 2003, and claimed a class of 6-mercaptocyclodextrin derivatives, ...
In January 2025, Wockhardt announced that ZAYNICH demonstrated unprecedented efficacy in a global, pivotal Phase III study ...
NEW YORK CITY, NY / ACCESS Newswire / December 2, 2025 / Merck Sharp & Dohme LLC ("Merck") recently suffered a data breach that compromised the sensitive personal data of individuals. This data breach ...
Attorneys from Gibbons have entered appearances for Merck Sharp & Dohme in a pending patent infringement lawsuit. The complaint, filed Sept. 5 in New Jersey District Court by Skiermont Derby and Sills ...
Merck Sharp & Dohme LLC has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis ...
(RTTNews) - Halozyme Therapeutics (HALO) filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in U.S. District Court in New Jersey. Halozyme believes the subcutaneous formulation of ...
Shares of Arbutus Biopharma slid after the company said the European Patent Office had revoked one of its patents. The stock slipped 12%, to $4.15, midday Friday, but has gained 29% in the past year.
Merck Sharp & Dohme LLC has patented new 5,6 saturated bicyclic heterocyles acting as NLRP3 inflammasome inhibitors potentially useful for the treatment of atherosclerosis, metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback